GlassScriptPhysician profile
Stephen S To
NPI 1790992709
$6,677.99
in general payments reported to CMS, 2019-2025
43 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $94.56 · 2021: $503 · 2022: $878 · 2023: $1,749 · 2024: $1,195 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,316.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,142.91 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $990.72 | 2019-2025 | |
| Novo Nordisk INC | $949.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $491.74 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $480.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $340.29 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $291.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $270.93 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Biohaven Pharmaceutical Holding Company LTD. | $231.21 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.30 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.72 | 2019-2025 | Jardiance |
| Amgen INC. | $110.78 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $104.09 | 2019-2021 | |
| Astellas Pharma US INC | $78.52 | 2019-2023 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $61.56 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen To listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.